Clinical Benefits of Luspatercept Dose Titration: Real-World Evidence

Opinion
Video

An expert on the treatment of patients with myelodysplastic syndromes provides clinical insights on dosing practices and considerations for luspatercept.

Case: SF3B1+ MDS-RS: IPSS-M-Guided 1L Luspatercept

Clinical Presentation:

70-year-old man diagnosed 6 months ago with LR-MDS with multilineage dysplasia - moderate anemia (Hb 11.2) and thrombocytosis (PLT 500,000 μl)

  • SF3B1 mutation positive
  • Non-del(5q)
  • No family history of cancer or significant genotoxic agent exposure
  • IPSS-R: Low
  • IPSS-M: SF3B1α mutation [SF3B1, ASXL1 and TET2 mutations]

Current Visit Clinical Workup and Diagnosis:

  • Serum EPO - 250m U/L, Ring sideroblast (RS) agnostic (either positive or negative)
  • Hgb: 8.2 g/dL.
  • WBC and ANC: WNL
  • PLT: 450,000 μl

He complains of increasing fatigue over the past 1-2 months. He normally plays 2-3 rounds of golf a week. Lately he has only been playing a full round once a week and maybe 9 holes on another day.

Initial Treatment(s):

  • The patient was started on luspatercept at the starting dose [1.0 mg/kg] as 1L therapy.
  • After 24 weeks, the patient has not received any transfusion and his Hgb is now 10.7 g/dL.
Recent Videos
Solly Chedid, MD, and Jamie Koprivnikar, MD
Solly Chedid, MD, and Jamie Koprivnikar, MD
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Related Content